Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer

Abstract

Methylation impairments are tightly associated with gene expression and molecular pathway deregulation in cancer development. However, other regulatory mechanisms exist, making it important to distinguish those from methylation driven changes. Here we specifically assessed molecular pathway states associated with gene methylation in lung adenocarcinoma.Paired gene expression and methylation data (id:GSE32867) were obtained from Gene Expression Omnibus. Self organizing maps (Wirth, H. et al.BMC Bioinformatics 2011;12:306 ) and in-house pathway signal flow algorithms were applied to describe expression (PSF) and methylation (mPSF) states in KEGG pathways.35 and 24 KEGG pathways had at least one branch deregulated at significance levels p<0.05 and 0.05<p < 0.1, respectively. Because many pathways are multibranch, our analysis totalled in 54 up- (PSF>1) and 73 down-regulated (PSF<1) branches. From these branches, 19 were positively (mPSF<0) or negatively (mPSF>0) correlated with methylation states (see table).

Top 8 KEGG pathway deregulations linked to gene methylation states

Pathway	Target	PSF	pPSF	mPSF (p<0.05)
Fc-g R-mediated phagocytosis	Regulation of cytoskeleton	0.75	0.07	93
"	ARF6	0.70	0.03	5
T cell receptor signaling	Anergy	0.83	0.08	20
PI3K-Akt signaling	Glucose uptake	0.81	0.07	-5
"	p53 signaling	0.81	0.09	-10
"	DNA repair	0.83	0.06	-32
ErbB signaling	DNA	0.84	0.07	-16
Adipocytokine signaling	ACSL1	1.23	0.08	-19

In conclusion, only ~15% of pathway deregulations were associated with changes in methylation state of genes, whereas the remainder should be attributed to other factors influencing gene expression, such as cancer-associated mutations, and alternative mechanisms of epigenetic control.

Rating:

Share or cite this content

Citations should be made in the following way:
L. Nersisyan, H. Wurth, A. Gevorgyan, H. Binder, A. Arakelyan (Yereven, Armenia; Leipzig, Germany). Methylation associated pathway activity deregulation in lung adenocarcinoma. Eur Respir J 2014; 44: Suppl. 58, 403

Member's Comments

No comment yet.

Related content which might interest you: Surface expression of CTLA-4 on CD4/CD25high cells in lung cancer Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Surface vs. intracellular CTLA-4 expression in lung cancer Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Telomere-associated gene network in lung adenocarcinoma Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey Year: 2015 The methylation profiling of multiple tumor suppressor genes in plasma cell-free DNA from patients with NSCLC versus non-malignant tumors - pilot study Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 The phenotypes and serum levels of alpha-1 antitrypsin in lung cancer patients – Preliminary results Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Molecular profiling of lung squamous carcinogenesis Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Expression and clinical implications of the estrogen receptor β in lung adenocarcinoma Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Prevalence of molecular changes in resected pulmonary adenocarcinomas Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 SMYD3 links lysine methylation of MAP3K2 to ras-driven lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 A requirement for IKKa in lung adenocarcinoma Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Mining common pathway deregulation profiles in lung diseases Source: International Congress 2014 – Molecular pathogenesis of pulmonary inflammatory diseases (COPD, asthma and ILD) Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Investigation of survivin gene expression in non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 LATE-BREAKING ABSTRACT: Decreased sirtuin expression in squamous cell carcinoma compared to adenocarcinoma Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014